Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
A live, multi-source view of Monte Rosa Therapeutics, Inc. (GLUE): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis.
Sector: Healthcare · Industry: Biotechnology · United States · 173 employees · monterosatx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Monte Rosa Therapeutics, Inc. (GLUE) had a market capitalization of $1.18B (forward -7.4) and a beta of 1.50; the shares traded in a 52-week range of $4.79 – $25.77 (199.6% over the year).
- Market cap
- $1.18B
- Enterprise value
- $597.6M
- Forward P/E
- -7.4
- Price / book
- 2.42
- EPS (trailing)
- $-1.68
- EPS (forward)
- $-1.88
- Payout ratio
- 0.0%
- 52-week range
- $4.79 – $25.77
- 52-week change
- 199.6%
- Beta
- 1.50
- Average volume
- 1.4M
- Shares outstanding
- 85.3M
- Short % of float
- 20.78%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Monte Rosa Therapeutics, Inc. (GLUE) last closed at $14.32 (the last completed close before that scan).
Technicals at the scan: RSI 40 (neutral territory), price -1.4% versus its 20-day average, 20-day versus 50-day average spread -21.3%, MACD histogram 0.25.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; analyst consensus score 81/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of GLUE; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-07-17). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Markus Warmuth (0B/1S). Who is trading what
RapidTradeView pick record
GLUE has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-08-28, rank #1, +3.33% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls Monte Rosa Therapeutics, Inc. (GLUE) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell GLUE.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.